BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22873408)

  • 21. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.
    Siddique MA; Nakanishi K; Taniguchi T; Grompe M; D'Andrea AD
    Exp Hematol; 2001 Dec; 29(12):1448-55. PubMed ID: 11750104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human alpha spectrin II and the Fanconi anemia proteins FANCA and FANCC interact to form a nuclear complex.
    McMahon LW; Walsh CE; Lambert MW
    J Biol Chem; 1999 Nov; 274(46):32904-8. PubMed ID: 10551855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53-TP53-Induced Glycolysis Regulator Mediated Glycolytic Suppression Attenuates DNA Damage and Genomic Instability in Fanconi Anemia Hematopoietic Stem Cells.
    Li X; Wu L; Zopp M; Kopelov S; Du W
    Stem Cells; 2019 Jul; 37(7):937-947. PubMed ID: 30977208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current knowledge on the pathophysiology of Fanconi anemia: from genes to phenotypes.
    Yamashita T; Nakahata T
    Int J Hematol; 2001 Jul; 74(1):33-41. PubMed ID: 11530803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical variability of Fanconi anemia (type C) results from expression of an amino terminal truncated Fanconi anemia complementation group C polypeptide with partial activity.
    Yamashita T; Wu N; Kupfer G; Corless C; Joenje H; Grompe M; D'Andrea AD
    Blood; 1996 May; 87(10):4424-32. PubMed ID: 8639804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants.
    Adachi D; Oda T; Yagasaki H; Nakasato K; Taniguchi T; D'Andrea AD; Asano S; Yamashita T
    Hum Mol Genet; 2002 Dec; 11(25):3125-34. PubMed ID: 12444097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector.
    Walsh CE; Nienhuis AW; Samulski RJ; Brown MG; Miller JL; Young NS; Liu JM
    J Clin Invest; 1994 Oct; 94(4):1440-8. PubMed ID: 7929819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
    van der Heijden MS; Brody JR; Dezentje DA; Gallmeier E; Cunningham SC; Swartz MJ; DeMarzo AM; Offerhaus GJ; Isacoff WH; Hruban RH; Kern SE
    Clin Cancer Res; 2005 Oct; 11(20):7508-15. PubMed ID: 16243825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of the Fanconi anemia group C protein activity results in an inability to activate caspase-3 after ionizing radiation.
    Guillouf C; Vit JP; Rosselli F
    Biochimie; 2000 Jan; 82(1):51-8. PubMed ID: 10717387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Fanconi anemia complementation group C protein corrects DNA interstrand cross-link-specific apoptosis in HSC536N cells.
    Marathi UK; Howell SR; Ashmun RA; Brent TP
    Blood; 1996 Sep; 88(6):2298-305. PubMed ID: 8822951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MxA overexpression reveals a common genetic link in four Fanconi anemia complementation groups.
    Li Y; Youssoufian H
    J Clin Invest; 1997 Dec; 100(11):2873-80. PubMed ID: 9389754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional interplay between BRCA2/FancD1 and FancC in DNA repair.
    Kitao H; Yamamoto K; Matsushita N; Ohzeki M; Ishiai M; Takata M
    J Biol Chem; 2006 Jul; 281(30):21312-21320. PubMed ID: 16687415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fanconi anaemia proteins: major roles in cell protection against oxidative damage.
    Pagano G; Youssoufian H
    Bioessays; 2003 Jun; 25(6):589-95. PubMed ID: 12766948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotypic correction of Fanconi anemia group C knockout mice.
    Gush KA; Fu KL; Grompe M; Walsh CE
    Blood; 2000 Jan; 95(2):700-4. PubMed ID: 10627482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct interactions of the five known Fanconi anaemia proteins suggest a common functional pathway.
    Medhurst AL; Huber PA; Waisfisz Q; de Winter JP; Mathew CG
    Hum Mol Genet; 2001 Feb; 10(4):423-9. PubMed ID: 11157805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in protein expression due to deleterious mutations in the FA/BRCA pathway.
    Salles D; Cabral RE; Pizzatti L; Bisch PM; Paixão JC; de Almeida CE; Seuánez HN; Cabral-Neto JB
    Biochem Biophys Res Commun; 2007 Dec; 364(4):755-60. PubMed ID: 17977515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia.
    Hess CJ; Ameziane N; Schuurhuis GJ; Errami A; Denkers F; Kaspers GJ; Cloos J; Joenje H; Reinhardt D; Ossenkoppele GJ; Zwaan CM; Waisfisz Q
    Cell Oncol; 2008; 30(4):299-306. PubMed ID: 18607065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human alpha spectrin II and the FANCA, FANCC, and FANCG proteins bind to DNA containing psoralen interstrand cross-links.
    McMahon LW; Sangerman J; Goodman SR; Kumaresan K; Lambert MW
    Biochemistry; 2001 Jun; 40(24):7025-34. PubMed ID: 11401546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Fanconi anemia pathway and DNA interstrand cross-link repair.
    Su X; Huang J
    Protein Cell; 2011 Sep; 2(9):704-11. PubMed ID: 21948210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Molecular basis of Fanconi's anemia].
    Digweed M
    Klin Padiatr; 1999; 211(4):192-7. PubMed ID: 10472548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.